Welcome to our dedicated page for BORA PHARMACEUTICALS news (Ticker: BORAY), a resource for investors and traders seeking the latest updates and insights on BORA PHARMACEUTICALS stock.
Bora Pharmaceuticals news covers pharmaceutical manufacturing agreements, CDMO activity, product launches, and updates from its subsidiary Upsher-Smith Laboratories. Recent company developments include renewed manufacturing work with GSK across commercial product lines, use of Bora’s Mississauga and Maple Grove manufacturing network, and U.S. launches tied to prescription generics and branded therapies.
Upsher-Smith-related news also covers resources for KYMBEE deflazacort Tablets, the Promise of Support Program, and generic portfolio expansion through products such as Ciprofloxacin and Dexamethasone Otic Suspension.
Upsher-Smith, a subsidiary of Bora Pharmaceuticals (OTCQX:BORAY), launched Cyclosporine Ophthalmic Emulsion 0.05%, a generic version therapeutically equivalent to Restasis. Bora received FDA ANDA approval in January 2026. According to IQVIA, the U.S. cyclosporine ophthalmic emulsion market totals about $1.9 billion.
The product is offered in 0.4 mL single-use vials in 30- and 60-count packages.
Upsher-Smith (BORAY) on April 14, 2026 launched dedicated caregiver and healthcare professional websites to support KYMBEE™ (deflazacort) Tablets for Duchenne muscular dystrophy patients aged 5 and older. The sites offer prescribing guides, patient support tools and the Promise of Support® program for coverage, delivery and continuity of therapy.
Bora Pharmaceuticals (BORAY) subsidiary Upsher-Smith launched a generic Ciprofloxacin 0.3% / Dexamethasone 0.1% Otic Suspension (NDC 0832-1430-75, 7.5 mL) on April 6, 2026. The product carries an AB therapeutic equivalence code and lists the brand Ciprodex as the reference listed drug.
According to the company, IQVIA reports U.S. market sales for this combination at approximately $118 million, and Upsher-Smith positions the launch as part of a portfolio diversification strategy.
Bora Pharmaceuticals and GSK (LSE/NYSE: GSK) renewed a five-year global manufacturing agreement through 2030, a deal reported at $250 million. The renewal gives GSK access to multiple Bora sites, including a new oral solid dose facility in Maple Grove, Minnesota.
Bora will continue manufacturing more than 20 commercial product lines (over 335 individual products) at its Mississauga site, supporting infectious disease, mental health, dermatology and other therapeutic areas.